Last reviewed 2026-04-20 · How we verify

Sertralin

Sertralin, marketed by Poznan University of Medical Sciences, is a treatment for depressive disorder with a key composition patent expiring in 2028. The drug's primary indication in the depressive disorder market positions it as a competitive player, though specific revenue figures are not provided. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Depressive disorder
• Obsessive-compulsive disorder
• Panic disorder
• Posttraumatic stress disorder
• Premenstrual dysphoric disorder
• Social phobia

Common side effects

• Nausea
• Diarrhea/Loose stool
• Tremor
• Dyspepsia
• Decreased appetite
• Hyperhidrosis
• Ejaculation failure
• Decreased libido
• Erectile dysfunction
• Ejaculation disorder
• Male sexual dysfunction
• Fever

Key clinical trials

• TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children (PHASE4)
• Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder (PHASE1)
• A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting Conditions (PHASE1)
• Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD (PHASE4)
• Treatment of Mild and Subthreshold Depressive Disorders (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sertralin CI brief — competitive landscape report
• Sertralin updates RSS · CI watch RSS
• Poznan University of Medical Sciences portfolio CI